EGFR and colorectal carcinoma: Interestingly, Schumacher and colleagues investigated a cohort of well-characterized CRC PDOs using targeted proteomics and identified heterogeneous activation of the mitogen-activated protein kinase (MAPK) signaling pathway, which contributed to differential responses to EGFR inhibition [66].